## Patent Claims

1. Compounds of the formula I




I

in which

$R^1$ denotes H or methyl,

$R^2$ denotes A or Het,

A denotes unbranched or branched alkyl with 1 - 8 C-Atoms, wherein one or two non-adjacent CH- and/or $CH_2$-groups may be replaced by N- or O-atoms and/or wherein 1-7 H-atoms may be replaced by F or Cl,

Het denotes pyrimidyl, pyridyl, pyridazinyl, pyrazinyl, piperidinyl, pyrrolidinyl, pyrazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, triazolyl, oxadiazolyl or thiadiazolyl, each of which is unsubstituted or mono- or disubstituted by Hal, A, CN, OH and/or OA,

Hal denotes F, Cl, Br or I,

with the proviso that, if $R^1$ is H, then $R_2$ is not 4-OMe,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1, in which

A denotes unbranched or branched alkyl with 1 - 8 C-Atoms, wherein one or two non-adjacent $CH_2$-groups may be replaced by O-atoms and/or wherein 1-3 H-atoms may be replaced by F,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2, in which

Het denotes pyrimidyl, pyridyl, pyridazinyl, pyrazinyl, piperidinyl, pyrrolidinyl, pyrazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, triazolyl, oxadiazolyl or thiadiazolyl, each of which is unsubstituted or monosubstituted by A,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to Claim 1, in which

$R^1$ denotes H or methyl,

$R^2$ denotes A or Het,

A denotes unbranched or branched alkyl with 1 - 8 C-Atoms, wherein one or two non-adjacent $CH_2$-groups may be replaced by O-atoms and/or wherein 1-3 H-atoms may be replaced by F,

Het denotes pyrimidyl, pyridyl, pyridazinyl, pyrazinyl, piperidinyl, pyrrolidinyl, pyrazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, triazolyl, oxadiazolyl or thiadiazolyl, each of which is unsubstituted or monosubstituted by A,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to Claim 1, selected from the group

| No. | Name |
|---|---|
| "A1" | 6-p-Tolyl-7*H*-imidazo[1,5-a]pyrazin-8-one |
| "A2" | 6-(4-tert-Butyl-phenyl)-7*H*-imidazo[1,5-a]pyrazin-8-one |

| | |
|---|---|
| "A3" | 6-(4-Trifluoromethyl-phenyl)-7*H*-imidazo[1,5-a]pyrazin-8-one |
| "A4" | 6-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-7*H*-imidazo[1,5-a]pyrazin-8-one |
| "A5" | 6-(4-Hydroxymethyl-phenyl)-7H-imidazo[1,5-a]pyrazin-8-one |
| "A6" | 6-[4-(1-Hydroxy-1-methyl-ethyl)-phenyl]-7H-imidazo[1,5-a]pyrazin-8-one |
| "A7" | 6-(4-tert-Butyl-phenyl)-3-methyl-7*H*-imidazo[1,5-a]pyrazin-8-one |
| "A8" | 6-[4-(1-Hydroxy-1-methyl-ethyl)-phenyl]-3-methyl-7H-imidazo[1,5-a]pyrazin-one |

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Process for the preparation of compounds of the formula I according to Claims 1-5 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that
a compound of the formula II




II

in which $R^1$ and $R^2$ have the meanings indicated in Claim 1, is debenzylated,
and/or
a base or acid of the formula I is converted into one of its salts.

7. Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures

thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

8. Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

9. Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.